Fangzhou Inc. (HK:6086)
:6086
6086 Stock Chart & Stats
HK$3.63
HK$0.21(4.98%)
At close: 4:00 PM EST
HK$3.63
HK$0.21(4.98%)
Day’s Range― - ―
52-Week RangeHK$1.20 - HK$6.20
Previous CloseN/A
Volume737.00K
Average Volume (3M)2.01M
Market Cap
HK$1.94B
Enterprise ValueHK$1.42B
Total Cash (Recent Filing)HK$294.17M
Total Debt (Recent Filing)HK$36.47M
Price to Earnings (P/E)233.7
Beta1.75
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,385,448,500
10 Day Avg. Volume2,214,042
30 Day Avg. Volume2,011,125
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)45.86
Price to Sales (P/S)2.23
P/FCF Ratio386.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.50Price Target Upside106.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$4.56B
Bulls Say, Bears Say
Bulls Say
Operating Cash Flow ImprovementA shift to positive operating cash flow is a durable improvement that reduces reliance on external financing and supports ongoing operating needs. For a drug manufacturer, sustained OCF helps fund trials, regulatory work and commercialization without immediate equity or debt raises.
Improved Liquidity And Liability ReductionReduction in total liabilities alongside higher cash balances strengthens financial flexibility and lowers short-term solvency risk. This provides the firm more runway to invest in development or restructure operations without immediate distressed financing decisions.
Positive Revenue GrowthSustained revenue growth suggests underlying market demand and commercial traction for products or services. For a pharmaceutical company, consistent top-line expansion offers a base to scale margins, justify continued R&D investment and pursue commercialization strategies over months.
Bears Say
Persistent Net Losses And Negative MarginsOngoing net losses and negative operating margins are structural red flags: they erode retained capital and limit reinvestment capacity. Without a credible pathway to sustained profitability, the company will struggle to fund growth and absorb shocks over the medium term.
Negative Equity And High LeverageNegative equity and high leverage materially constrain strategic flexibility, increase refinancing risk, and can limit access to capital. Over months, this heightens insolvency risk and can force dilutive financing or asset sales if cash generation slips.
Weak Free Cash Flow And Cash ConversionLow free cash flow and poor cash conversion mean the business cannot reliably turn accounting profits into spendable cash. This limits ability to deleverage, invest in late-stage trials or scale commercial activities without recurring external funding.
Fangzhou Inc. News
6086 FAQ
What was Fangzhou Inc.’s price range in the past 12 months?
Fangzhou Inc. lowest stock price was HK$1.20 and its highest was HK$6.20 in the past 12 months.
What is Fangzhou Inc.’s market cap?
Fangzhou Inc.’s market cap is HK$1.94B.
When is Fangzhou Inc.’s upcoming earnings report date?
Fangzhou Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 146 days.
How were Fangzhou Inc.’s earnings last quarter?
Fangzhou Inc. released its earnings results on Mar 19, 2026. The company reported HK$0 earnings per share for the quarter, the consensus estimate of N/A by HK$0.
Is Fangzhou Inc. overvalued?
According to Wall Street analysts Fangzhou Inc.’s price is currently Undervalued.
Does Fangzhou Inc. pay dividends?
Fangzhou Inc. does not currently pay dividends.
What is Fangzhou Inc.’s EPS estimate?
Fangzhou Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fangzhou Inc. have?
Fangzhou Inc. has 1,385,448,500 shares outstanding.
What happened to Fangzhou Inc.’s price movement after its last earnings report?
Fangzhou Inc. reported an EPS of HK$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -6.04%.
Which hedge fund is a major shareholder of Fangzhou Inc.?
Currently, no hedge funds are holding shares in HK:6086
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fangzhou Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.98%
12-Months-Change
Fundamentals
Return on Equity
7.59%
Trailing 12-Months
Asset Growth
28.27%
Trailing 12-Months
Company Description
Fangzhou Inc.
Fangzhou Inc. provides online chronic disease management services in China. The company provides services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory chronic diseases. It offers H2H services, including online medical consultation services, e-prescription, and prescription refill services through mobile application; and healthcare products through online retail pharmacy service platform, as well as operates hospitals and offline pharmacies. The company was founded in 2015 and is based in Guangzhou, China.
6086 Stock 12 Month Forecast
Average Price Target
HK$7.50
▲(106.61% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Luye Pharma Group
―
Tong Ren Tang Technologies Co
―
Xinte Energy Co., Ltd. Class H
―
SenseTime Group, Inc. Class B
―